|
Renal function
|
CKD (3 to 5 stages)
|
CKD (4 and 5 stages)
|
CKD (3 stage)
|
|---|
|
No-KA (n = 175)
|
KA (n = 148)
|
p value*
|
No-KA (n = 52)
|
KA (n = 70)
|
p value*
|
No-KA (n = 123)
|
KA (n = 78)
|
p value*
|
|---|
|
eGFR (mL/min/1.73 m2)
|
|
Baseline
|
38.7 ± 14.1
|
30.7 ± 13.1
|
0.000
|
20.7 ± 6.2
|
19.1 ± 6.8
|
0.187
|
46.4 ± 8.4
|
41.1 ± 7.4
|
0.000
|
|
End-point
|
43.3 ± 20.7
|
31.4 ± 17.5
|
0.000
|
21.8 ± 11.5
|
19.4 ± 13.0
|
0.295
|
52.4 ± 16.5
|
42.1 ± 13.5
|
0.000
|
|
Scr (μmol/L)
|
|
Baseline
|
187.0 ± 98.1
|
226.4 ± 107.7
|
0.001
|
296.7 ± 116.2
|
305.5 ± 108.4
|
0.669
|
140.6 ± 28.2
|
155.3 ± 28.4
|
0.000
|
|
End-point
|
186.3 ± 116.2
|
246.1 ± 136.8
|
0.000
|
298.1 ± 130.2
|
337.6 ± 140.2
|
0.115
|
139.0 ± 67.8
|
163.9 ± 60.1
|
0.009
|
|
BUN (mmol/L)
|
|
Baseline
|
10.2 ± 5.2
|
11.9 ± 5.6
|
0.008
|
15.4 ± 6.2
|
15.6 ± 5.6
|
0.854
|
8.0 ± 2.5
|
8.5 ± 2.7
|
0.233
|
|
End-point
|
10.1 ± 5.4
|
13.8 ± 8.0
|
0.000
|
14.7 ± 5.8
|
19.0 ± 8.3
|
0.002
|
8.1 ± 3.7
|
9.2 ± 3.9
|
0.053
|
|
UA (μmol/L)
|
|
Baseline
|
412.7 ± 113.4
|
425.3 ± 100.1
|
0.293
|
437.6 ± 114.9
|
422.2 ± 112.6
|
0.462
|
402.1 ± 111.5
|
428.1 ± 88.0
|
0.068
|
|
End-point
|
383.8 ± 89.1
|
373.8 ± 83.8
|
0.307
|
399.8 ± 105.0
|
357.3 ± 94.2
|
0.023
|
377.0 ± 81.0
|
388.9 ± 70.3
|
0.289
|
|
\( HCO_{3}^{ - } \)
(mmol/L)
|
|
Baseline
|
22.5 ± 3.3
|
22.3 ± 3.1
|
0.546
|
20.7 ± 3.0
|
21.0 ± 2.9
|
0.493
|
23.2 ± 3.1
|
23.4 ± 2.8
|
0.762
|
|
End-point
|
24.1 ± 2.7
|
22.9 ± 2.7
|
0.000
|
22.8 ± 2.5
|
21.8 ± 2.2
|
0.018
|
24.6 ± 2.6
|
23.9 ± 2.6
|
0.054
|
- Italic values indicate significance of p value (p < 0.05)
- * Presented as comparison of the No-KA group with the KA group (t-test)
